Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
Titel:
Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
Auteur:
Robinson, Jennifer G. Farnier, Michel Kastelein, John J.P. Roth, Eli M. Taskinen, Marja-Riitta Colhoun, Helen M. Brunet, Aurelie DiCioccio, A. Thomas Lecorps, Guillaume Pordy, Robert Baccara-Dinet, Marie T. Cannon, Christopher P.